Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor (ORLIFAT)
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Control
Capolac
Flax fiber
Capolac+Flax fiber
Sponsored by

About this trial
This is an interventional supportive care trial for Obesity focused on measuring Obesity, orlistat, fat excretion, fiber, dairy calcium
Eligibility Criteria
Inclusion Criteria:
- 20-60 years of age
- men and women
- BMI 30-40 kg/m2
Exclusion Criteria:
- Dairy allergy and/or intolerance, allergy to Orlistat
- Infectious and metabolic diseases
- Gastrointestinal diseases (previous and current)
- Troubles swallowing tablets and capsules
- Dietary supplement use during the trial and 1 month prior to the trial
- Postmenopausal (selfreported)
- Pregnancy and lactation
- Treatment with oral anticoagulation medications, ciclosporin, levothyroxin, antiepileptika, acarbose and amiodaron
- Prescription medication will be considered on an individual basis at the screening visit according to SOP
- Dieting or other changes of diet within 3 months
- Participation in other trials
Sites / Locations
- Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Arm Label
Control
Capolac
Flax fiber
Capolac+Flax fiber
Arm Description
Alli treatment plus placebo (rice flour)
Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
Outcomes
Primary Outcome Measures
Ratings of gastrointestinal comfort
Subjective assessment of gastrointestinal comfort using visual analogue scales
Secondary Outcome Measures
Total fecal fat excretion
Average total fecal fat excreted during five days in week 0 and week 4
Total, LDL and HDL cholesterol
Ratings of quality of life
Questionnaire used to assess quality of life related to obesity and treatment thereof
Body weight
Waist and hip circumference
food intake
Intake of total fat and energi estimated using 7d weighed food records
Habitual intake of dietary fiber and calcium
Habitual intake of dietary fiber and calcium estimated using food frequency questionnaires
Full Information
NCT ID
NCT01320228
First Posted
March 21, 2011
Last Updated
September 1, 2014
Sponsor
University of Copenhagen
Collaborators
GlaxoSmithKline
1. Study Identification
Unique Protocol Identification Number
NCT01320228
Brief Title
Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor
Acronym
ORLIFAT
Official Title
Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
June 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Copenhagen
Collaborators
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of the Orlifat trial is to investigate if dietary fibres from linseeds and dairy calcium (Capolac ®) may reduce gastrointestinal side effects related to increased fecal fat content, induced by treatment with Alli® (orlistat). Secondly, effect on food intake, anthropometry, Quality of Life and cardiovascular risk markers will be evaluated. The trial is designed as a randomised 2 x 2 factorial 13-weeks parallel intervention, in which 72 obese participants will be randomised to supplementation with flaxseed fibres and/or dairy calcium concentrate (Capolac) in addition to treatment with Alli ®:
Alli® (60 mg t.i.d) plus placebo (rice flour)
Alli® plus 5 g flaxseed fibers
Alli® plus 1200 mg Ca from Capolac
Alli® plus 5 g flaxseed fibers and 1200 mg Ca from Capolac
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, orlistat, fat excretion, fiber, dairy calcium
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
69 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Alli treatment plus placebo (rice flour)
Arm Title
Capolac
Arm Type
Experimental
Arm Description
Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
Arm Title
Flax fiber
Arm Type
Experimental
Arm Description
Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
Arm Title
Capolac+Flax fiber
Arm Type
Experimental
Arm Description
Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
Intervention Type
Dietary Supplement
Intervention Name(s)
Control
Intervention Description
Alli treatment plus placebo (rice flour)
Intervention Type
Dietary Supplement
Intervention Name(s)
Capolac
Intervention Description
Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
Intervention Type
Dietary Supplement
Intervention Name(s)
Flax fiber
Intervention Description
Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
Intervention Type
Dietary Supplement
Intervention Name(s)
Capolac+Flax fiber
Intervention Description
Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
Primary Outcome Measure Information:
Title
Ratings of gastrointestinal comfort
Description
Subjective assessment of gastrointestinal comfort using visual analogue scales
Time Frame
baseline, week 0, 2, 4, 8, 12
Secondary Outcome Measure Information:
Title
Total fecal fat excretion
Description
Average total fecal fat excreted during five days in week 0 and week 4
Time Frame
week 0 and 4
Title
Total, LDL and HDL cholesterol
Time Frame
baseline and 12
Title
Ratings of quality of life
Description
Questionnaire used to assess quality of life related to obesity and treatment thereof
Time Frame
baseline, week 0, 2, 4, 8 and 12
Title
Body weight
Time Frame
baseline, week 0, 2, 4, 6, 8, 10 and 12
Title
Waist and hip circumference
Time Frame
Baseline, week 0, 2, 4, 6, 8, 10 and 12
Title
food intake
Description
Intake of total fat and energi estimated using 7d weighed food records
Time Frame
week 0 and 4
Title
Habitual intake of dietary fiber and calcium
Description
Habitual intake of dietary fiber and calcium estimated using food frequency questionnaires
Time Frame
baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
20-60 years of age
men and women
BMI 30-40 kg/m2
Exclusion Criteria:
Dairy allergy and/or intolerance, allergy to Orlistat
Infectious and metabolic diseases
Gastrointestinal diseases (previous and current)
Troubles swallowing tablets and capsules
Dietary supplement use during the trial and 1 month prior to the trial
Postmenopausal (selfreported)
Pregnancy and lactation
Treatment with oral anticoagulation medications, ciclosporin, levothyroxin, antiepileptika, acarbose and amiodaron
Prescription medication will be considered on an individual basis at the screening visit according to SOP
Dieting or other changes of diet within 3 months
Participation in other trials
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arne Astrup, MD, Dr.med.
Organizational Affiliation
Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen
Official's Role
Study Director
Facility Information:
Facility Name
Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen
City
Frederiksberg C
ZIP/Postal Code
1958
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
28191026
Citation
Kristensen M, Juul SR, Sorensen KV, Lorenzen JK, Astrup A. Supplementation with dairy calcium and/or flaxseed fibers in conjunction with orlistat augments fecal fat excretion without altering ratings of gastrointestinal comfort. Nutr Metab (Lond). 2017 Feb 7;14:13. doi: 10.1186/s12986-017-0164-8. eCollection 2017.
Results Reference
derived
Learn more about this trial
Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor
We'll reach out to this number within 24 hrs